Pharma

Your Article Summary

See Latest Articles

Antineoplastic Agent / Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Tarceva®Application for Approval of Additional Indication of Pancreatic Cancer
Chugai Pharmaceutical Co., 09/21/09

Chugai Pharmaceutical Co., Ltd. announced that the company filed an application with the Japanese Ministry of Health, Labour and Welfare for the approval of an additional indication of pancreatic cancer for the antineoplastic agent / epidermal growth factor receptor tyrosine kinase inhibitor, "TARCEVA Tablet 25 mg and 100 mg" [generic name: erlotinib hydrochloride] (hereafter, Tarceva®).

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals